Jefferies Financial Group Inc. Buys New Position in GH Research PLC (NASDAQ:GHRS)

Jefferies Financial Group Inc. bought a new stake in shares of GH Research PLC (NASDAQ:GHRS) in the first quarter, HoldingsChannel.com reports. The institutional investor bought 750,000 shares of the company’s stock, valued at approximately $8,272,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Two Sigma Investments LP bought a new position in GH Research in the fourth quarter worth $117,000. Millennium Management LLC bought a new position in GH Research in the fourth quarter worth $145,000. BNP Paribas Financial Markets bought a new position in GH Research in the fourth quarter worth $44,000. Northern Trust Corp raised its holdings in GH Research by 26.8% in the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after purchasing an additional 8,641 shares in the last quarter. Finally, Woodline Partners LP raised its holdings in GH Research by 112.0% in the fourth quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock worth $553,000 after purchasing an additional 41,711 shares in the last quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Trading Down 4.3%

NASDAQ GHRS opened at $13.74 on Friday. GH Research PLC has a 12 month low of $6.00 and a 12 month high of $20.50. The stock has a market cap of $714.89 million, a P/E ratio of -17.39 and a beta of 0.97. The stock’s fifty day moving average price is $13.82 and its 200-day moving average price is $11.90.

GH Research (NASDAQ:GHRS) last released its earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.42. As a group, analysts forecast that GH Research PLC will post -0.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on GHRS shares. Cantor Fitzgerald started coverage on GH Research in a report on Wednesday, June 4th. They issued an “overweight” rating and a $25.00 price objective for the company. Guggenheim decreased their price objective on GH Research from $32.00 to $29.00 and set a “buy” rating for the company in a report on Friday, May 9th. Wall Street Zen upgraded GH Research from a “sell” rating to a “hold” rating in a report on Saturday, July 5th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Friday, May 9th. Finally, JMP Securities reissued a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a research note on Tuesday, June 24th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.00.

GH Research Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).